A new platform collaboration positions generative AI drug discovery infrastructure at the center of RNA interference therapeutics development, as Insilico Medicine and Ribo formalize an arrangement that extends AI-guided design and automated experimental execution into the oligonucleotide modality.
Insilico Medicine (HKEX: 03696.HK), a Hong Kong-listed AI drug discovery company, and Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938.HK), a clinical-stage oligonucleotide therapeutics company, announced a strategic collaboration agreement on May 12, 2026, combining Insilico’s Pharma.AI platform and LifeStar 2 automated laboratory with Ribo’s oligonucleotide therapeutics development capabilities. The arrangement deepens a pre-existing experimental services relationship and is structured to cover the full R&D workflow, from target identification through clinical translation.
Platform contributions and collaboration structure
The Insilico Medicine Ribo collaboration is structured as a technology empowerment arrangement rather than an asset-specific co-development deal. Insilico contributes two core platform elements: Pharma.AI, its end-to-end generative AI drug discovery platform covering target screening, molecular design, data modeling, and clinical efficacy and safety prediction; and LifeStar 2, an automated biology laboratory with high-throughput experimental capacity. Ribo, which was listed on the Hong Kong Stock Exchange in January 2026, contributes domain expertise in oligonucleotide therapeutics development along with its vertically integrated R&D infrastructure.
Ribo’s platform suite includes RiboGalSTAR, a proprietary liver-targeting delivery technology that has advanced seven products to clinical stages across cardiovascular, metabolic, renal, and liver disease indications, and RiboPepSTAR, an extrahepatic delivery platform with preclinical evidence in kidney, cardiac, metabolic, and adipose tissue applications. The collaboration is intended to apply Insilico’s AI and automation layer across multiple stages of Ribo’s development workflow, including siRNA target discovery, drug molecule design and optimization, and AI-assisted clinical translation. No financial specifics of any kind were disclosed.
Ribo noted that it had previously used Insilico’s LifeStar 2 laboratory for high-throughput experimental services, making it the first partner on that platform. The new agreement formalizes and expands that relationship into a broader strategic framework.